tert-butyl (2-(3-amino-5-(trifluoromethyl)phenyl)propan-2-yl)carbamate | 942077-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (2-(3-amino-5-(trifluoromethyl)phenyl)propan-2-yl)carbamate
• 英文别名: tert-butyl (2-[3-amino-5-(trifluoromethyl)phenyl]propan-2-yl)carbamate；Tert-butyl {1-[3-amino-5-(trifluoromethyl)phenyl]-1-methylethyl}carbamate；tert-butyl N-[2-[3-amino-5-(trifluoromethyl)phenyl]propan-2-yl]carbamate
• CAS: 942077-11-4
• 化学式: C₁₅H₂₁F₃N₂O₂
• 分子量: 318.339
• InChiKey: QILJCQLKPYZYHA-UHFFFAOYSA-N

物化性质

• 沸点：
  384.4±42.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(3-amino-5-(trifluoromethyl)phenyl)propan-2-yl)carbamate 、 (2S)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

  摘要：

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

  DOI：

  10.1021/jm101479y
• 作为产物：
  描述：

  3-氨基-5-溴三氟甲苯 在 正丁基锂 、 硫酸 、 盐酸羟胺 、 对甲苯磺酸 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 乙二醇 、 甲苯 为溶剂， 反应 172.67h， 生成 tert-butyl (2-(3-amino-5-(trifluoromethyl)phenyl)propan-2-yl)carbamate
  参考文献：
  名称：

  Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

  摘要：

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

  DOI：

  10.1021/jm101479y

文献信息

• [EN] FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS<br/>[FR] COMPOSÉS D'URÉE TRICYCLIQUES CONDENSÉS COMME INHIBITEURS DE RAF KINASE ET/OU DE DIMÈRES DE RAF KINASE
  申请人：BEIGENE LTD

  公开号：WO2014206343A1

  公开（公告）日：2014-12-31

  Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

  提供了某些融合的三环脲化合物及其盐、组合物以及使用方法。
• Bicyclic compounds with kinase inhibitory activity
  申请人：Calderwood F. Emily

  公开号：US20070149533A1

  公开（公告）日：2007-06-28

  The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

  本发明提供了一种新颖的双环化合物，可用作蛋白激酶抑制剂。本发明还提供了包括本发明化合物的制药组合物以及使用该组合物治疗各种疾病的方法。
• Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
  申请人：BeiGene, Ltd.

  公开号：US10208038B2

  公开（公告）日：2019-02-19

  Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

  本文提供了某些熔融三环脲化合物及其盐类、其组合物以及使用方法。
• FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS
  申请人：BeiGene, Ltd.

  公开号：EP3013798B1

  公开（公告）日：2018-06-27
• US8110687B2
  申请人：——

  公开号：US8110687B2

  公开（公告）日：2012-02-07